Kornimate/medical-research-clean huggingface dataset:
vestibular stimulation and neurodevelopmental technique on hypotonic cerebral palsy while controlling the gender

Conditions: Cerebral Palsy; Hypotonia

Summary: there is no such article found who specifies the effects of sensory integration therapies like vestibular stimulation technique or developmental milestone while controlling the gender of children with cerebral palsy. so, there is a need to do more research work on this in future to find out best treatment approach for children with cerebral palsy of their respective gender. that is why this study will focus on the results of vestibular stimulation and neurodevelopmental technique while controlling the gender distribution of both intervention groups to find out the effects of these interventions that wither, they have some influence on the participants or not.

bobath concept of neurodevelopment in children with cerebral palsy, is a problem-solving approach to the assessment and treatment of individuals with disturbances of tone, movement, and function due to a lesion of cns, the goal of treatment is to optimize function by improving postural control and selective movement through facilitation. but also, no study found which specifically focuses the improvements on boys and girl's ratio or their gender-based improvements of tone or developmental milestones. different swings such as infant swing, frog swing, platform swing will be included as mode of vestibular stimulation treatment. on the other side, stimulation of vestibular system improved child's postural control and motor function in many studies.

Eligibility criteria:
inclusion criteria: * hypotonic cp * gmfm-88 ranges: with true score of zero (0) = does not initiates i.e., head control absent at age of 6 months * tone: 6 months infants total scoring ≤ 54 and 8 month or more total scoring ≤ 68 on infant neurological international battery scoring sheet will be included. exclusion criteria: * children with other abnormalities and pathologies like down syndrome, joubert syndrome * children undergone any kind of surgery like reconstruction surgeries for congenital defects of eyes, head, neck or all four limbs of the body * children with other type of cerebral palsy (cp) like spastic (hypertonic), choreoathetoid, dystonic, ataxia, athetoid and mixed cp * children with any other neurological deficits, mentally challenged.

Keywords: developmental milestones hypotonia vestibular stimulation
a us study to evaluate transarterial radioembolization (tare) in combination with durvalumab and bevacizumab therapy in people with unresectable hepatocellular carcinoma amenable to tare

Conditions: Hepatocellular Carcinoma (HCC)

Summary: the purpose of this study is to measure the efficacy and safety of durvalumab intravenous (iv) solution plus bevacizumab iv solution after transarterial radioembolization (yttrium 90 glass microspheres tare) in participants with unresectable hepatocellular carcinoma (hcc) amenable to embolization.

a phase ii single-arm study conducted in participants with unresectable hepatocellular carcinoma (hcc) eligible for embolization and not eligible for or who have declined treatment with resection and/or ablation or liver transplant. participants with previous transarterial chemoembolization (tace) or tare associated with the curative setting are permitted with a 6-month washout. approximately 125 participants with unresectable but amenable to locoregional therapy hcc eligible for embolization will be enrolled in the study at approximately 20 sites in the us to treat approximately 100 participants.

Eligibility criteria:
inclusion criteria: * participants with confirmed unresectable hcc * participants with lung dose threshold for yttrium 90 glass microspheres of 30 gy (equal or less than 30 gy per treatment for glass) and an estimated future liver remnant volume (flrv) ≥ 30% of whole liver volume * participants with no evidence of extrahepatic disease on any available imaging * participants with one or more measurable lesions, unilobar disease for participants with segmental or right anterior/posterior portal vein invasion (vp1/vp2) and eligible for yttrium 90 glass microspheres tare. * participants having child-pugh score class a. * participants having ecog performance status of 0 or 1 at enrollment * adequate organ and marrow function exclusion criteria: * disease amenable to curative surgery, ablation or transplantation. * participants co-infected with hbv and hdv * any history of nephrotic or nephritic syndrome. * clinically significant (eg, active) cardiovascular disease * participants with uncontrolled hypertension * history of hepatic encephalopathy * known hereditary predisposition to bleeding or thrombosis; any prior or current evidence of bleeding diathesis. * receipt of more than 1 prior embolization (tace or tare) treatment/procedure * participant has received any prior anticancer systemic therapy for unresectable hcc. * history of arterial thrombotic event, including myocardial infarction, unstable angina, cerebrovascular accident, or transient ischemic attack, within 6 months prior to enrollment. * history of abdominal fistula or gastrointestinal (gi) perforation, non-healed gastric ulcer that is refractory to treatment, or active gi bleeding within 6 months prior to enrollment

Keywords: tare durvalumab bevacizumab liver cancer y90
a prospective observational study to evaluate long-term changes in cartilage morphology in subjects who previously received tpx-100 or placebo in study tpx-100-1 for patellar osteoarthritis involving both knees

Conditions: Mild to Moderate Knee OA

Summary: to evaluate the long-term changes in patellar cartilage thickness in tpx-100 versus placebo-treated knees in subjects who participated in study tpx-100-1 or tpx-100-2.

no drug intervention. study to collect 1 additional mri of each knee treated in either tpx-100-1 or tpx-100-2.

Eligibility criteria:
inclusion criteria: * subjects who participated in tpx-100-1 and received 4 injections of 200 mg/injection tpx-100 in one knee, or subjects who participated in tpx-100 * cruciate and collateral ligament stability as assessed by screening history and clinical examination * stable medial and lateral menisci as assessed by screening history and clinical examination * able to read, understand, sign and date the subject informed consent exclusion criteria: * contraindication to mri, including: metallic fragments, clips or devices in the brain, eye, or spinal canal; implanted devices that are magnetically programmed; weight \> 300 lbs.; moderate or severe claustrophobia; previous intolerance of mri procedure * prior surgery in the knees, excluding procedures for debridement only (no previous microfracture procedure) * history of rheumatoid arthritis, psoriatic arthritis, or any other autoimmune or infectious cause for arthritis * last viscosupplementation (e.g. synvisc® or similar hyaluronic acid product) injected into either knee \< 3 months before enrollment * last intra-articular knee injection of corticosteroids \< 3 months before enrollment * use of any steroids (except inhaled corticosteroids for allergy or respiratory problems) during the previous month before enrollment * history of arthroscopy in either knee in the 3 months before enrollment * history of septic arthritis, gout or pseudo-gout in either knee in the 12 months before enrollment * clinical signs of acute meniscal tear (locking, new acute mechanical symptoms consistent with meniscal tear) * active systemic infection * participation in other clinical osteoarthritis drug studies, except for studies tpx-100-1 and tpx-100-2, within two years prior to enrollment in tpx-100-4.
antimicrobial stewardship reduces mdro isolates in critically ill patients

Conditions: Sepsis

Summary: antimicrobial exposure is known to reduce the selection for various drug-resistant organisms. numerous studies have demonstrated the association between antimicrobial use and mdr bacteria detection. however, to the investigators knowledge, there is few data to support the concept that reducing antibiotic use actually leads to improvements in antibiotic susceptibilities. moreover, antimicrobial stewardship was demonstrated to reduce mdro and was strongly recommended in clinics. as the investigators know, antimicrobial overuse, which occurs commonly in china, induces a severe antibacterial resistance. china's ministry of health (moh) has established a policy about the antimicrobial stewardship. to date, the investigators do not have published documentation the effects of this policy on multidrug-resistant organism (mdro) in critically ill patients.


Eligibility criteria:
inclusion criteria: * patients hospitalized in the icu exclusion criteria: * patients who were readmitted to the icu during a single hospital stay

Keywords: antimicrobial stewardship
group based treatment for persons with social communication difficulties

Conditions: Brain Injuries

Summary: a large proportion of patients with abi have cognitive deficits that affect the way they communicate. cognitive difficulties with attention, memory, executive functions and so on affect social communication. without successful social skills, a person may engage in conflicts, become isolated and be denied access to social and vocational opportunities. internationally, several group interventions have been developed for treating social communication difficulties during the last years. group interactive structured treatment (gist) is a validated holistic multidisciplinary group treatment targeting social communication skills after traumatic brain injury. the main aim of the present study is to examine the efficacy of gist for improving social communication in persons with acquired brain injury, including tbi, stroke, tumor ect. secondary the study aims to compare the standard gist protocol to an newly developed intensive gist protocol. efficacy will be assessed immediately after intervention, but also three and six months after the intervention. the project is in line with international research efforts aimed to establish more knowledge about group treatment for persons with social communication disorders after abi.


Eligibility criteria:
inclusion criteria: * traumatic brain injury (tbi), cerebrovascular accidents (stroke; cva) patients with no concomitant diseases minimum 6 months post-injury * the patient are experiencing social communication disorders * the family member is experiencing the patients social communication disorders * the patient is motivated and expresses a desire to change communication behavior * one close family member is able to participate in the intervention process * adequate norwegian language proficiency to participate in the group * the patient experiences moderate to severe difficulties with minimum 3 aspects of communication assessed with la trobe questionnaire * the patient have insight into their communication difficulties (minimum intellectual insight) assessed with awareness questionnaire exclusion criteria: * age \<18 years * aphasia. based on previous records. * major psychiatric disorder or reported ongoing alcohol or substance abuse * premorbid neurological disease or insult and/or comorbid neurological disease * impaired basic linguistic, mnemonic, motor, or perceptual function that can interfere with the ability to engage with the training or intelligence quotient (iq) \< 85

Keywords: adults rehabilitation social communication disorder cognitive communication disorder groups evidence-based
effects of flavanoids in essential hypertension, type 2 diabetes and healthy persons

Conditions: Vascular Complications, Diabetic

Summary: flavanols are natural substances who are frequently found in our nutrition. a lot of research has already been executed in the past to investigate what effects this flavanols could have in the human population. based on these examinations, the investigators think and suggest that flavanols can have positive effects on the vascularly system, more specifically on the peripheral and cerebral blood vessels. the effects are only observed in a healthy populations, meanwhile patient populations like diabetes patients could really benefit from this. this is why the investigators will execute this study.

the study population is divided into 3 main groups, namely healthy controls, patients with diabetes type 2 (defined by american diabetes association's (ada)) and patients with essential hypertension (the latter group is again divided into 3 subgroups: use of betablockers, angiotensin-converting enzyme (ace)-inhibitors, angiotensin-receptor blockers (arbs). each main goup will consist of minimal 20 subjects. in this interventional study the investigators ask the patient to come twice. one time they get capsules with real flavanols and the other time they get capsules with a placebo. the study will be double blinded so nor the investigators, nor the patients now at which investigation they get the real flavanols or the placebo. before and after the intake of these capsules, a few measurements will take place. these measurements will be compared on the one hand with the second investigation day (inter-patients and intra-patient) and on the other hand with the pre-intake measurements (intra-patient). the different examinations are a flow-mediated dilatation (fmd) test, blood pressure analysis and an exercise test. the investigator who performs the fmd-test, followed a course and needed to pass an examination. the blood pressure measurements will be continuously for 20 minutes to avoid to much bias.

Eligibility criteria:
inclusion criteria: * men and woman, age 18 - 85 years old, diabetes type 2 and/or using 1 sort of blood pressure lowering medication (betablockers, calcium-antagonists, raas-inhibitors) exclusion criteria: * general: diabetes type 1, maturity-onset diabetes of youth (mody), latent autoimmune diabetes of the adult (lada), smokers, alcohol abuse, active cancer, chronic inflammatory disease * microvascular: retinopathy, diabetic/hypertensive nephropathy, peripheral sensoric neuropathy, autonomic neuropathy * macrovascular: cardiovascular diseases, cerebrovascular diseases, active or chronic palindromic vasculitis * medication with impact on endothelial function: no-containing medication, phosphodiesterase type 5 -inhibitors * diseases who can affect the exercise test: chronic obstructive pulmonary disease (copd) with global initiative for chronic obstructive lung disease (glod) -stages iii and iv, heart failure class 3 and 4, serious musculoskeletal diseases * other: pregnancy

Keywords: flavanols diabetes type 2 essential hypertension peripheral vascular function
evaluation of plasma vitamin c levels in a population of chronic rheumatism in immuno-rheumatology

Conditions: Lupus or SLE; Spondyloarthritis

Summary: scurvy is an almost forgotten carential pathology, caused by a deep vitamin c (or ascorbic acid) deficiency, a priori exceptional in industrialized countries. according to the french national authority for health standards, hypovitaminosis c is defined as a plasma vitamin c level of less than 23 μmol/l. this deficiency would affect 5 to 10% of the general population in industrialized countries and from 17% (clinical scurvy) to 47% (biological hypovitaminosis c) of vulnerable populations (malnutrition, hospitalized patients...). vitamin c is essential for collagen synthesis. it plays a cofactor role in the synthesis of catecholamines precursors and takes action in synthesis of certain amino acids. in rheumatology, pain is a recurring reason for consultation. in a context of treated chronic inflammatory rheumatism (ric), while most of patients seem in remission or in reduced activity of their disease, all real-life studies show that 30 to 40% of them complain of residual pain, 70% of chronic fatigue and 20-25% of symptoms similar to secondary fibromyalgia. currently, authors suggest the interest of vitamin c analgesic properties, especially in musculoskeletal pain, due to the role of ascorbic acid in neurotransmitters. vitamin c would act as a cofactor for a family of biosynthetic and regulatory metalloenzymes. thus, the authors suggest the potential of vitamin c in an analgesic mechanism involving the biosynthesis of opioid peptides.


Eligibility criteria:
inclusion criteria: * patient over 18 years-old, * followed for chronic inflammatory rheumatism (ric): spondylo-arthritis (including spondylitis and psoriatic rheumatism) and lupus, * with ric in remission or low activity definec according to the following criteria: bath ankylosing spondylitis disease activity index (basdai) criteria and bath ankylosing spondylitis fonctional index (basfi) questionnaire for spondylitis and psoriatic rheumatism, systemic lupus erythematosus disease activity index (sledai) 2k score for lupus, * having given written consent after written and oral information, * member of the social security system, * basic treatment for the disease not modified for at least 6 months, without modification at baseline * persistence of painful complaints not objectively explained by his ric. exclusion criteria: * pregnant or nursing patient, * patient protected by law or under guardianship or curatorship, or not able to participate in a clinical trial under l.1121-16 article of french public health regulations, * patient participating in or having participated in another drug clinical trial in the month prior to inclusion.
orlistat treatment of crigler-najjar disease

Conditions: Crigler-Najjar Syndrome

Summary: the purpose of this study was to determine whether orlistat is effective in decreasing plasma unconjugated bilirubin levels in patients with crigler-najjar disease.

unconjugated hyperbilirubinemia in crigler-najjar (cn) disease is conventionally treated with phototherapy and/or phenobarbital. life-long daily phototherapy has considerable disadvantages. main problems are a decreasing efficacy with age and a profound impact of the intensive phototherapy regimen on the quality of (social) life. an alternative treatment option for unconjugated hyperbilirubinemia is based on intestinal capture of ucb by oral treatment. particularly when plasma ucb concentrations are high as in cn disease, ucb can diffuse from the blood into the intestinal lumen across the mucosa. intestinal capture of ucb followed by fecal excretion reduces the enterohepatic circulation of ucb and subsequently decreases plasma ucb concentration. we demonstrated in gunn rats, the animal model for cn disease, that orlistat treatment decreases plasma ucb concentrations parallel with increased fecal fat excretion, and induces net transmucosal excretion of ucb from the blood into the intestinal lumen. in human adults, orlistat has been widely applied for treatment of obesity, without serious side effects. recent studies in obese adolescents and prepubertal children indicate that short-term orlistat treatment is well-tolerated by children and generally has only mild side effects. in the present randomized, placebo-controlled trial we determined in patients with cn disease the effects of orlistat treatment on plasma ucb concentrations, and on fecal excretion of fat and ucb.

Eligibility criteria:
inclusion criteria: * patients with crigler-najjar disease above the age of 7 years exclusion criteria: * cholestasis, chronic malabsorption syndrome, pregnancy

Keywords: crigler-najjar disease. bilirubin. phototherapy. orlistat. unconjugated hyperbilirubinemia.
arabic version of the ears questionnaire

Conditions: Knee Osteoarthritis; Low Back Pain

Summary: a study to translate and cross-culturally adapt the exercise adherence rating scale (ears) into the arabic language, and assess its psychometric properties.


Eligibility criteria:
inclusion criteria: * low back pain patients: aged 18 years or older, experienced non-specific clbp of 3 months or longer, pain localized to the lumbar region. * knee oa patients: eligible participants must meet the knee oa diagnostic criteria according to the american college of rheumatology (acr). exclusion criteria: * degenerative systemic diseases * neurological symptoms * lumbar stenosis * spondylolisthesis * history of spinal or knee surgeries * pregnancy * rheumatoid arthritis * serious pathological conditions (inflammatory arthritis and malignancy) * individuals who cannot read and understand documents written in the arabic language.
real-life study with nivolumab (bms-936558) in advanced nsclc patients after prior chemotherapy

Conditions: Non-Small Cell Lung Cancer

Summary: this study intends to describe the real-life effectiveness and safety of nivolumab in advanced nsclc patients in germany, as well as the patient profile, pattern of use and the quality of life.


Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed diagnosis of locally advanced or metastatic nsclc, stage iiib/stage iv * decision to initiate a treatment with nivolumab for the first time already undertaken by physician * males and females, ≥18 years of age exclusion criteria: * current primary diagnosis of a cancer other than advanced nsclc. example: a cancer other than nsclc that requires systemic or other treatment. * pre-treatment with nivolumab and/or ipilimumab (pre-treatment with checkpoint-inhibitors other than nivolumab and ipilimumab, and tyrosine kinase inhibitors(tkis) is allowed) * current participation in an interventional clinical trial for treatment of nsclc. (patients who have completed their participation in an interventional trial or who are not receiving study drug anymore and who are only followed-up for overall survival can be enrolled. for blinded studies, the treatment administered needs to be known) other protocol defined inclusion/exclusion criteria could apply
assessing speech perception and amplification benefit during infancy

Conditions: Hearing Loss; Children With Hearing Differences; Amplification; Speech Perception

Summary: the goal of this project is to compare aided and unaided speech discrimination among infants with hearing loss and a cohort of infants with typical hearing. working hypothesis: among this group of infants with hearing loss, performance will be significantly better when infants are tested while using amplification (i.e., aided condition) compared to when tested without amplification (i.e., unaided condition). infants fit with optimally programmed amplification will perform similarly to the infants with typical hearing on speech discrimination tasks.


Eligibility criteria:
inclusion criteria: * children between the ages of 6 months and 36 months (inclusive) at the time of enrollment. * english is the primary spoken language in the home * demonstrated ability to complete a conditioned head turn via visual reinforcement audiometry (vra) * if normal hearing -normal hearing sensitivity bilaterally * if hearing loss * children with diagnosis of bilateral sensorineural hearing ranging from mild to severe * children currently using hearing aids * children currently enrolled in intervention exclusion criteria: * children born earlier than 35 weeks gestation * children with abnormal tympanometry on the day of testing * children with concerns of secondary disabilities * children with auditory neuropathy * concerns of hearing loss in normal hearing children